UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 6-K
 
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of May, 2011
 
Commission File Number: 000-51933
 
 
LABOPHARM INC.
 
480 Armand-Frappier Blvd.
Laval, Québec, Canada
H7V 4B4
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F x
Form 40-F o
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Yes  o
No  x
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
 
Yes  o
No  x
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes  o
No  x
 
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-   .
 
 

 
 
 
 
 
TABLE OF CONTENTS
 
Exhibit
Description
   
99.1
 
Report on Voting Results
 

 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
LABOPHARM INC.
 
       
Date: May 5, 2011
By:
/s/  Mark A. D’Souza  
    Name: Mark A. D’Souza  
    Title: President and Chief Executive Officer  
       
 
 
 

 
Labopharm Inc. (MM) (NASDAQ:DDSS)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Labopharm Inc. (MM) Charts.
Labopharm Inc. (MM) (NASDAQ:DDSS)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Labopharm Inc. (MM) Charts.